ClinicalTrials.gg
Not yet recruitingNCT06647602THRIVEUpdated Feb 10, 2026

Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy

An observational study in Differentiated Thyroid Cancer, Thyroid Cancer and Levothyroxine, sponsored by University Medical Center Groningen. Not yet recruiting at 2 sites in Netherlands. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by University Medical Center Groningen · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Thyroid Neoplasms with a site in Netherlands — 6 open to participants now, 8 under way, 1 of them phase 3. Thyroid Neoplasms · Netherlands.

Started
2026
with 1 other
Observational
4 of 28
1 open now
Registered
28th of 28
by date
Lead sponsor
5 of 28
University Medical Center Groningen

Among the 28 studies in Thyroid Neoplasms with a site in Netherlands, this one is one of 2 that started in 2026, is one of 4 observational ones, and was the 28th registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

6 of the 28 studies in Thyroid Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Thyroid Neoplasms with a site in Netherlands, or all of them as a file.
02

Study summary

This study will be a multicentre prospective cohort study on TH-substitution after thyroid hormone withdrawal preceding radioiodine treatment.

Read the detailed description

While treatment with L-T4 after TH-withdrawal is widely used in DTC patients to suppress TSH and improve hypothyroid symptoms, the value of L-T3 addition in initiation of TH treatment has not been evaluated in this context. Lifelong monotherapy with L-T3 should not be preferred over L-T4 yet, short-term use of L-T3 to initiate TH-supplementation can be safely implemented. We hypothesize that initial treatment with L-T4+L-T3 combination treatment can have a more direct effect on TSH-levels and earlier relieve of hypothyroid symptoms resulting in a better QoL. We will conduct a prospective cohort study comparing the initiation of TH-supplementation after TH-withdrawal in two cohorts of DTC patients: patients receiving L-T4+LT3 with a gradually decrease of L-T3 dose in time, and patients receiving L-T4 only. We will compare potency to suppress TSH, effect on QoL and effects on thyroid- and cardiovascular parameters. Patients (18-75 years) diagnosed with high-risk DTC after TH-withdrawal will be eligible for inclusion. The primary objective is to compare the proportion of patients reaching target TSH-levels after two weeks of substitution with L-T3 or L-T4.

Secondary objectives are to compare the effects of L-T4+L-T3 or L-T4 in the first 3 months of treatment on serum thyroid parameters TSH and Tg, quality of life, and cardiovascular parameters

03

Conditions studied

  • Differentiated Thyroid Cancer
  • Thyroid Cancer
  • Levothyroxine
  • Liothyronine
  • Thyroid Hormones

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This study will include patients with a histologically confirmed high-risk DTC, men and women aged 18-75 years. Patients have to be prepared to RAI with TH-withdrawal and treated according to the ATA guidelines.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed DTC (papillary thyroid carcinoma, follicular thyroid carcinoma, oncocytic thyroid carcinoma)
  • Classified as high-risk DTC according to the ATA guidelines or, patients for whom the risk of a recurrence is estimated to be higher based on clinical features (assessed by their treating physician).
  • Prepared for RAI-therapy with TH-withdrawal
  • Patients must be fit to adhere to the study protocol
  • Patients must be able to read and understand the Dutch language

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Patients with comorbidities, such as severe heart failure, (poorly controlled) atrial fibrillation, of which the treating physician decides that L-T3 is unsuitable.
  • Conditions or drugs interfering with thyroid hormone uptake:
  • Patients with a history of atrophic gastritis
  • Patients using proton-pomp inhibitors
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • TH-combination cohort

    L-T4+L-T3 combination according to local protocol.

    Drug: Cytomel (liothyronine)

  • Levothyroxine cohort

    L-T4 monotherapy according to local protocol.

    Drug: Euthyrox (levothyroxine)

Interventions

  • DrugThyroxineStudies of ThyroxineThyroxine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Euthyrox (levothyroxine sodium tablets; L-T4) is a thyromimetic synthetic drug identical to T4. Patients will recieve levothyroxine (euthyrox) in a dose of 2 μg × kg body weight / day.

  • DrugTriiodothyronineStudies of TriiodothyronineTriiodothyronine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cytomel (liothyronine sodium tablets; L-T3) is a thyromimetic synthetic drug identical to T3. The patients in this cohort recieve L-T4+L-T3 combination therapy. The L-T4 dose will be 2 μg × kg body weight / day, equal to the dose in the other interventional arm. L-T3 will be added twice daily from the first day of combination treatment, in dosages gradually decreasing from 25 ug 2/day to 5 ug 2/day over a time span of 3 weeks after which L-T3 is stopped.

06

What researchers measure

Primary outcomes

  1. TSH after two weeks of TH substitution

    The percentage of patients reaching target TSH (\<0.5 mU/L) after two weeks of L-T3+L-T4 substitution compared to patients with L-T4-substitution.

    Time frame: Before and after 2 weeks of TH-substitution

Secondary outcomes

  1. TSH (mU/L)

    The % of decrease of serum thyroid parameters TSH after 1, 2, 4, 6, and 12 weeks of TH-substitution.

    Time frame: Before and after 1, 2, 4, 6, and 12 weeks of TH-substitution.

  2. Thyroglobulin (Tg; ng/mL)

    The % of decrease of serum thyroid parameters Tg after 1, 2, 4, 6, and 12 weeks of TH-substitution. Tg is a precursor of T3 and T4 and is a measurement for remaining thyroid (cancer) cells. Tg-levels are affected by TSH and therefore, we expect by reducing TSH-levels to also reduce Tg levels. Consecutive Tg-measurements in this study act as a secondary measure for TH substitution. Since Tg-values between patients variable, we will use the % decrease instead of absolute values.

    Time frame: Before and after 1, 2, 4, 6, and 12 weeks of TH-substitution

  3. QoL in patients treated with L-T3 or L-T4

    Quality of life will be assessed using standardized QoL questionnaires for thyroid- and thyroid cancer patient reported outcome. Our aim is to compare improvement of hypothyroid symptoms after initiation of therapy, and evaluate whether sings of hyperthyroidism and possible overtreatment are present. We will use the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 (core measure QoL questionnaire) in combination with the THYCA-QoL (additional thyroid cancer-specific part).

    Time frame: Before and after 2, 6, and 12 weeks of TH-substitution

  4. Heart rate (HR; bpm)

    Cardiovascular parameters will be assessed during visits to the outpatient clinic before initiation of TH-substitution (during hypothyroidism) and after 6 weeks of TH-treatment. Patients will be compared intra- and interindividually.

    Time frame: Before and after 6 and 12 weeks of TH-substitution

  5. Blood pressure (BP; mmHg)

    Cardiovascular parameters will be assessed during visits to the outpatient clinic before initiation of TH-substitution (during hypothyroidism) and after 6 and 12 weeks of TH-treatment. Patients will be compared intra- and interindividually.

    Time frame: Before and after 6 and 12 weeks of TH-substitution

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — Handling of personal data complies with the General Data Protection Regulation (GDPR; in Dutch: De uitvoeringswet algemene verorderning gegevensbescherming [UAVG]). Encoded data will be kept for 15 years after closure of the study and can only be used for ancillary studies after strict approval of the study protocol by the project leader (dr. W. Zandee).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Mar 2028, 18 months later.

Of 103 non-industry observational studies under Thyroid Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 311. This study's planned 18 months is below that.

Counting every sponsor, half of 112 studies reached it within 63 months; a quarter within 26 and three quarters within 311.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2024
First posted
Oct 18, 2024
StartEst.
Sep 1, 2026
Primary completionEst.
Mar 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06647602
Responsible party
Sponsor
First posted
Oct 18, 2024
Start date
Sep 1, 2026 (estimated)
Primary completion
Mar 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Feb 10, 2026

Study contacts

Mirthe Links, BSc
Contact
m.h.links@umcg.nl
+31 50 3610973
Wouter Zandee, MD/PhD
Contact
w.t.zandee@umcg.nl
+31 50 3613731
Wouter Zandee, MD/PhD
principal investigator · University Medical Center Groningen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion